Your browser doesn't support javascript.
loading
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.
Szarek, Michael; Reijnders, Esther; Steg, Ph Gabriel; Jukema, J Wouter; Schwertfeger, Markus; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Fazio, Sergio; Garon, Genevieve; Goodman, Shaun G; Harrington, Robert A; White, Harvey D; Zeiher, Andreas M; Cobbaert, Christa; Schwartz, Gregory G.
Afiliação
  • Szarek M; Division of Cardiology, University of Colorado School of Medicine, Box B130, Aurora, CO 80045, USA.
  • Reijnders E; CPC Clinical Research, 2115 N. Scranton Street, Suite 2040, Aurora, CO 80045, USA.
  • Steg PG; Department of Epidemiology and Biostatistics, State University of New York, Downstate Health Sciences University School of Public Health, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.
  • Jukema JW; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, LUMC Main Building, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
  • Schwertfeger M; Université Paris-Cité, 85 boulevard Saint-Germain, 75006 Paris, France.
  • Bhatt DL; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, 46 rue Henri Huchard, 75018 Paris, France.
  • Bittner VA; Institut Universitaire de France, 1 rue Descartes, 75005 Paris, France.
  • Diaz R; Department of Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
  • Fazio S; Netherlands Heart Institute, Moreelsepark 1, 3511 EP Utrecht, The Netherlands.
  • Garon G; RCardiometabolism, Neuroscience, Endocrinology, PHCS, PoC, RDS Clinical Development and Medical Affairs (CDMA), Roche Diagnostics International Ltd., Building 5/Floor 10, Forrenstrasse 2, 6343 Rotkreuz, Switzerland.
  • Goodman SG; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, 1 Gustave Levy Place, Box 1030, New York, NY 10029, USA.
  • Harrington RA; Division of Cardiovascular Disease, University of Alabama at Birmingham, 701 19th Street South - LHRB 310, Birmingham, AL 35294, USA.
  • White HD; Estudios Cardiológicos Latino América, Instituto Cardiovascular de Rosario, Paraguay 160, Rosario, Santa Fe, Rosario 2000, Argentina.
  • Zeiher AM; Scientific Council -Cardiometabolic Global Development, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
  • Cobbaert C; Global Medical Department - General Medicines GBU, Sanofi, Ontario M2R 3T4, Canada.
  • Schwartz GG; Canadian VIGOUR Centre, University of Alberta, 87 Ave NW, Edmonton, Alberta T6G 2E1, Canada.
Eur J Prev Cardiol ; 31(10): e75-e78, 2024 Aug 09.
Article em En | MEDLINE | ID: mdl-38501249
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Lipoproteína(a) / Anticorpos Monoclonais Humanizados Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Prev Cardiol Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Lipoproteína(a) / Anticorpos Monoclonais Humanizados Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Prev Cardiol Ano de publicação: 2024 Tipo de documento: Article